Emerging evidence suggests that sphingolipid metabolism is involved in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). This study aimed to evaluate the diagnostic and prognostic value of sphingolipid-related genes in IPF and to identify potential sphingolipid-associated biomarkers.
Sphingolipid-related genes were obtained from the GeneCards database. Non-negative matrix factorization (NMF) was performed to identify molecular clusters and differentially expressed genes (DEGs). High-dimensional weighted gene co-expression network analysis (hdWGCNA) was used to determine fibroblast-associated genes. The intersecting genes were used to construct diagnostic and prognostic models using multiple machine learning algorithms. Hub genes were identified from the overlap between the diagnostic and prognostic signatures. In silico gene knockout was conducted using scTenifoldKnk. Functional validation was performed using Cell Counting Kit-8 (CCK-8) assay, wound healing assay, quantitative real-time polymerase chain reaction (RT-qPCR), and western blotting (WB).
Three molecular clusters with significant prognostic differences were identified. hdWGCNA revealed 60 key fibroblast-associated genes. Diagnostic and prognostic models constructed from these genes showed promising diagnostic and prognostic utility across independent cohorts, while the prognostic model exhibited some degree of cohort-dependent variability. CCDC80 was identified as a hub gene associated with sphingolipid-defined molecular heterogeneity and fibroblast-related transcriptional programs. scTenifoldKnk analysis indicated that simulated CCDC80 knockout affected fibrosis-related signaling pathways. In vitro experiments demonstrated that CCDC80 knockdown attenuated fibroblast proliferation, migration, and fibrotic activation.
This study identified sphingolipid-related molecular signatures with potential diagnostic and prognostic value in IPF and highlighted CCDC80 as a candidate profibrotic regulator. Further validation in larger and clinically standardized cohorts is required before clinical translation.
Not applicable.
Yi Liao, Lingjing Yang, Xiaoshu Liu et al.· Orphanet Journal of Rare Dis...· 0 citations
Aptamers are widely used in biosensing and targeted therapeutics, yet reported data remain fragmented across unstructured text, tables, and figures. Existing databases are limited in coverage and diversity, which constrains computational modeling. Here, we present AptaNexus (https://www.aptanexus.com/), a multitier aptamer database containing over 12,000 sequences targeting 1900 molecular entities, curated from literature published between 2005 and 2025. Its extraction pipeline, Dual-LLM Extraction with Reverse Grounding (Dual-LLMs+RG), achieves an F1 score of 0.970 at a fraction of the cost of the state-of-the-art model. Records are stratified into four quality tiers, supporting both experimental selection and machine learning applications. Beyond conventional keyword search, AptaNexus incorporates the Model Context Protocol (MCP) and an embedded conversational agent, Chat Aptamer, enabling natural-language queries that return structured, source-linked, and application-oriented recommendations. For example, users can request detection of a target in blood to receive a ranked list of aptamers with validated sensor platforms or query drug delivery targets to obtain functionally annotated candidates. By combining large-scale, evidence-grounded data with agent-accessible interfaces, AptaNexus makes aptamer information readily accessible across disciplines and, for the first time, provides native AI-agent interoperability.
Fangyuan Zheng, Lingjing Yang, Jilie Kong et al.· Analytical Chemistry· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.